JP2017128614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017128614A5 JP2017128614A5 JP2017091305A JP2017091305A JP2017128614A5 JP 2017128614 A5 JP2017128614 A5 JP 2017128614A5 JP 2017091305 A JP2017091305 A JP 2017091305A JP 2017091305 A JP2017091305 A JP 2017091305A JP 2017128614 A5 JP2017128614 A5 JP 2017128614A5
- Authority
- JP
- Japan
- Prior art keywords
- release layer
- pharmaceutical composition
- dibutyl sebacate
- magnesium stearate
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 14
- PYGXAGIECVVIOZ-UHFFFAOYSA-N dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 10
- 229940031954 dibutyl sebacate Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000003111 delayed Effects 0.000 claims 7
- 235000019359 magnesium stearate Nutrition 0.000 claims 7
- 230000002459 sustained Effects 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 239000001856 Ethyl cellulose Substances 0.000 claims 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 5
- 229940117841 Methacrylic Acid Copolymer Drugs 0.000 claims 5
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims 5
- 229920001249 ethyl cellulose Polymers 0.000 claims 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 5
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 5
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 5
- 229940068968 Polysorbate 80 Drugs 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Adhd patch Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 3
- 229940057948 Magnesium stearate Drugs 0.000 claims 3
- 229960001344 Methylphenidate Drugs 0.000 claims 3
- 229960004667 ethyl cellulose Drugs 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 239000002269 analeptic agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466684P | 2011-03-23 | 2011-03-23 | |
| US61/466,684 | 2011-03-23 | ||
| US201161561763P | 2011-11-18 | 2011-11-18 | |
| US61/561,763 | 2011-11-18 | ||
| US201261591129P | 2012-01-26 | 2012-01-26 | |
| US61/591,129 | 2012-01-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016058474A Division JP2016117767A (ja) | 2011-03-23 | 2016-03-23 | 注意欠陥障害の処置のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017128614A JP2017128614A (ja) | 2017-07-27 |
| JP2017128614A5 true JP2017128614A5 (es) | 2018-02-08 |
| JP6325148B2 JP6325148B2 (ja) | 2018-05-16 |
Family
ID=46879766
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501292A Active JP6043785B2 (ja) | 2011-03-23 | 2012-03-23 | 注意欠陥障害の処置のための方法および組成物 |
| JP2016058474A Withdrawn JP2016117767A (ja) | 2011-03-23 | 2016-03-23 | 注意欠陥障害の処置のための方法および組成物 |
| JP2017091305A Active JP6325148B2 (ja) | 2011-03-23 | 2017-05-01 | 注意欠陥障害の処置のための方法および組成物 |
| JP2018179001A Withdrawn JP2018197276A (ja) | 2011-03-23 | 2018-09-25 | 注意欠陥障害の処置のための方法および組成物 |
| JP2020035076A Withdrawn JP2020079322A (ja) | 2011-03-23 | 2020-03-02 | 注意欠陥障害の処置のための方法および組成物 |
| JP2022030878A Withdrawn JP2022066315A (ja) | 2011-03-23 | 2022-03-01 | 注意欠陥障害の処置のための方法および組成物 |
| JP2023223409A Pending JP2024019726A (ja) | 2011-03-23 | 2023-12-28 | 注意欠陥障害の処置のための方法および組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501292A Active JP6043785B2 (ja) | 2011-03-23 | 2012-03-23 | 注意欠陥障害の処置のための方法および組成物 |
| JP2016058474A Withdrawn JP2016117767A (ja) | 2011-03-23 | 2016-03-23 | 注意欠陥障害の処置のための方法および組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018179001A Withdrawn JP2018197276A (ja) | 2011-03-23 | 2018-09-25 | 注意欠陥障害の処置のための方法および組成物 |
| JP2020035076A Withdrawn JP2020079322A (ja) | 2011-03-23 | 2020-03-02 | 注意欠陥障害の処置のための方法および組成物 |
| JP2022030878A Withdrawn JP2022066315A (ja) | 2011-03-23 | 2022-03-01 | 注意欠陥障害の処置のための方法および組成物 |
| JP2023223409A Pending JP2024019726A (ja) | 2011-03-23 | 2023-12-28 | 注意欠陥障害の処置のための方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9028868B2 (es) |
| EP (4) | EP3272342B1 (es) |
| JP (7) | JP6043785B2 (es) |
| KR (2) | KR20160135373A (es) |
| CN (2) | CN103608004A (es) |
| AU (3) | AU2012230733B2 (es) |
| BR (1) | BR112013024401B1 (es) |
| CA (1) | CA2830788C (es) |
| DK (3) | DK3272342T3 (es) |
| ES (3) | ES2644942T3 (es) |
| MX (3) | MX357551B (es) |
| PT (3) | PT2688557T (es) |
| SG (2) | SG193587A1 (es) |
| WO (1) | WO2012129551A1 (es) |
| ZA (1) | ZA201307649B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241391B2 (en) * | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) * | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) * | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US10905652B2 (en) * | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) * | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| GB201319791D0 (en) * | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| CA3018328A1 (en) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| IL255343B1 (en) * | 2015-05-04 | 2024-06-01 | Confluence Pharmaceuticals Llc | Essay formulations of acamprosate |
| JP6796132B2 (ja) * | 2015-07-17 | 2020-12-02 | ビーイー ファーベル マニュファクチャリング | 液体剤形中の薬学的活性化合物放出性多層微小粒子 |
| US10383825B2 (en) | 2015-08-13 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | Calcium alginate dosage formulations, and methods of making and using thereof |
| US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
| WO2017173068A1 (en) * | 2016-03-30 | 2017-10-05 | University Of Maryland, Baltimore | Microparticulate system for colonic drug delivery |
| JP2019517469A (ja) * | 2016-05-26 | 2019-06-24 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ピプラドロールを用いる行動症候群の治療方法 |
| WO2018009566A1 (en) * | 2016-07-06 | 2018-01-11 | Durect Corporation | Oral dosage form with drug composition, barrier layer and drug layer |
| US9931303B1 (en) * | 2017-02-06 | 2018-04-03 | Alcobra Ltd. | Abuse deterrent formulations of amphetamine |
| US20180256515A1 (en) * | 2017-03-10 | 2018-09-13 | Adare Pharmaceuticals, Inc. | Oral amphetamine composition |
| AU2018256998B2 (en) * | 2017-04-28 | 2023-11-09 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration comprising |
| CA3062834A1 (en) | 2017-05-17 | 2018-11-22 | Confluence Pharmaceuticals, Llc | Formulations of homotaurines and salts thereof |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| CN108653243B (zh) * | 2018-03-30 | 2019-03-22 | 江苏南农高科动物药业有限公司 | 一种缓释替米考星微囊粉的制备方法 |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| EP3662900A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
| BR112021014593A2 (pt) * | 2019-01-25 | 2021-10-05 | Ironshore Pharmaceuticals & Development, Inc. | Composições de metilfenidato para tratamento de transtorno de déficit de atenção e hiperatividade |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8322007D0 (en) | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
| US4904476A (en) | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| DK0384646T3 (da) | 1989-02-16 | 1993-07-12 | British Tech Group | Dispenseringsindretning |
| JP2558396B2 (ja) | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| JP2916978B2 (ja) | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
| US5658590A (en) | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
| GB9514451D0 (en) | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
| US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
| US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
| MX9805870A (es) | 1996-01-22 | 1999-01-31 | ||
| DE69716713T2 (de) | 1996-02-02 | 2003-07-03 | Medeva Europ Ltd | Verfahren zur herstellung von d-threo-(r,r)-methylphenidat und recycling nicht erwünschter enantiomere durch epimerisierung |
| ATE212336T1 (de) | 1996-03-08 | 2002-02-15 | Medeva Europ Ltd | Auflösungsverfahren von threo-methylphenidate |
| GB9606417D0 (en) | 1996-03-27 | 1996-06-05 | Chiroscience Ltd | Asymmetric cyclisation |
| AU4801497A (en) | 1996-09-30 | 1998-04-24 | Alza Corporation | Dosage form and method for administering drug |
| US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| EP1782798A3 (en) | 1996-11-25 | 2008-05-21 | Alza Corporation | Ascending-dose dosage form |
| ATE325606T1 (de) | 1996-11-25 | 2006-06-15 | Alza Corp | Dosisform mit ansteigender dosisfreisetzung |
| WO1998025902A1 (en) | 1996-12-13 | 1998-06-18 | Medeva Europe Limited | The preparation of enantiomerically-enriched threo-methylphenidate |
| GB9700912D0 (en) | 1997-01-17 | 1997-03-05 | Chiroscience Ltd | Resolution |
| US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
| WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
| DE69939748D1 (de) | 1998-11-02 | 2008-11-27 | Elan Pharma Int Ltd | Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
| US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
| US6384020B1 (en) | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
| US6500459B1 (en) | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| GB9918735D0 (en) * | 1999-08-09 | 1999-10-13 | Straken Limited | Transdermal patches |
| US6898455B2 (en) | 1999-10-29 | 2005-05-24 | The Mclean Hospital Corporation | Method for providing optimal drug dosage |
| US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
| US6569456B2 (en) | 2000-01-13 | 2003-05-27 | Osmotica Corp. | Osmotic device containing diltiazem and an ACE inhibitor or diuretic |
| US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6520921B1 (en) | 2000-06-20 | 2003-02-18 | Eastman Kodak Company | Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication |
| US6344215B1 (en) | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
| US20030232890A1 (en) | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
| US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| US20040137062A1 (en) | 2001-05-25 | 2004-07-15 | Sham Chopra | Chronotherapy tablet and methods related thereto |
| CA2448558A1 (en) | 2001-07-10 | 2003-01-23 | Teva Pharmaceutical Industries, Ltd. | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
| US6811794B2 (en) | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US6726624B2 (en) | 2002-03-06 | 2004-04-27 | The Mclean Hospital Corporation | Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| MXPA05002623A (es) | 2002-09-09 | 2005-05-05 | Biovail Lab Inc | Formulaciones cronoterapeuticas de diltiazem y la administracion de las mismas. |
| US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
| US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| US7910128B2 (en) | 2003-01-03 | 2011-03-22 | Supernus Pharmaceuticals, Inc. | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics |
| NZ544162A (en) | 2003-05-29 | 2008-09-26 | Shire Llc | Abuse resistant amphetamine compounds |
| US20050031688A1 (en) | 2003-08-04 | 2005-02-10 | Ayala William J. | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
| BRPI0507180A (pt) | 2004-01-29 | 2007-06-26 | Pfizer | derivados de 1-isopropil-2-oxo-1,2-diidropiridina-3-carboxamida tendo atividade agonìstica de receptor 5-ht4 |
| ES2261006B1 (es) * | 2004-06-10 | 2007-11-01 | Laboratorios Rubio, S.A. | Pellet multicapa de liberacion controlada de metilfenidato. |
| EP1846040A2 (en) | 2005-01-28 | 2007-10-24 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| FR2892937B1 (fr) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
| ES2627127T3 (es) | 2006-05-09 | 2017-07-26 | Mallinckrodt Llc | Formas de dosificación sólidas de liberación modificada de orden cero |
| BRPI0621633A2 (pt) * | 2006-05-12 | 2011-12-13 | Shire Llc | composição farmacêutica, método para tratar distúrbio de déficit de atenção por hiperatividade (adhd) e composição farmacêutica de liberação sustentada |
| US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| FR2901478B1 (fr) * | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee |
| CN1985810A (zh) * | 2006-07-28 | 2007-06-27 | 中国人民解放军第二军医大学 | 盐酸哌甲酯缓控释胶囊及其制备方法 |
| KR100888131B1 (ko) | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| JP5377317B2 (ja) | 2006-10-30 | 2013-12-25 | ハナル バイオファーマ カンパニー リミテッド | 放出性が制御されたアンジオテンシン−ＩＩ−受容体遮断剤とＨＭＧ−ＣｏＡ還元酵素阻害剤の複合組成物 |
| US9114071B2 (en) | 2007-04-04 | 2015-08-25 | Sigmoid Pharma Limited | Oral pharmaceutical composition |
| WO2009035473A2 (en) | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| JP5774853B2 (ja) * | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬投薬形 |
| CA2627198A1 (en) | 2008-03-27 | 2009-09-27 | Pharmascience Inc. | Methylphenidate extended release therapeutic drug delivery system |
| US8901113B2 (en) | 2009-09-30 | 2014-12-02 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
-
2012
- 2012-03-23 CN CN201280024451.8A patent/CN103608004A/zh active Pending
- 2012-03-23 PT PT127600682T patent/PT2688557T/pt unknown
- 2012-03-23 AU AU2012230733A patent/AU2012230733B2/en active Active
- 2012-03-23 EP EP17187023.1A patent/EP3272342B1/en active Active
- 2012-03-23 US US13/429,292 patent/US9028868B2/en active Active
- 2012-03-23 ES ES12760068.2T patent/ES2644942T3/es active Active
- 2012-03-23 BR BR112013024401-1A patent/BR112013024401B1/pt active IP Right Grant
- 2012-03-23 PT PT211742192T patent/PT4011364T/pt unknown
- 2012-03-23 CA CA2830788A patent/CA2830788C/en active Active
- 2012-03-23 MX MX2013010920A patent/MX357551B/es active IP Right Grant
- 2012-03-23 PT PT171870231T patent/PT3272342T/pt unknown
- 2012-03-23 DK DK17187023.1T patent/DK3272342T3/da active
- 2012-03-23 ES ES17187023T patent/ES2883589T3/es active Active
- 2012-03-23 KR KR1020167032196A patent/KR20160135373A/ko not_active Application Discontinuation
- 2012-03-23 KR KR1020137027522A patent/KR101834033B1/ko active IP Right Grant
- 2012-03-23 DK DK12760068.2T patent/DK2688557T3/da active
- 2012-03-23 EP EP21174219.2A patent/EP4011364B1/en active Active
- 2012-03-23 JP JP2014501292A patent/JP6043785B2/ja active Active
- 2012-03-23 CN CN201910483969.1A patent/CN110151731A/zh active Pending
- 2012-03-23 MX MX2021000431A patent/MX2021000431A/es unknown
- 2012-03-23 ES ES21174219T patent/ES2973539T3/es active Active
- 2012-03-23 EP EP12760068.2A patent/EP2688557B1/en active Active
- 2012-03-23 DK DK21174219.2T patent/DK4011364T3/da active
- 2012-03-23 EP EP23215283.5A patent/EP4316488A3/en active Pending
- 2012-03-23 SG SG2013071279A patent/SG193587A1/en unknown
- 2012-03-23 WO PCT/US2012/030472 patent/WO2012129551A1/en active Application Filing
- 2012-03-23 SG SG10201901167SA patent/SG10201901167SA/en unknown
-
2013
- 2013-09-23 MX MX2022013590A patent/MX2022013590A/es unknown
- 2013-10-15 ZA ZA2013/07649A patent/ZA201307649B/en unknown
-
2016
- 2016-03-23 JP JP2016058474A patent/JP2016117767A/ja not_active Withdrawn
- 2016-09-16 AU AU2016228307A patent/AU2016228307A1/en not_active Abandoned
-
2017
- 2017-05-01 JP JP2017091305A patent/JP6325148B2/ja active Active
-
2018
- 2018-03-21 AU AU2018202002A patent/AU2018202002B2/en active Active
- 2018-09-25 JP JP2018179001A patent/JP2018197276A/ja not_active Withdrawn
-
2020
- 2020-03-02 JP JP2020035076A patent/JP2020079322A/ja not_active Withdrawn
-
2022
- 2022-03-01 JP JP2022030878A patent/JP2022066315A/ja not_active Withdrawn
-
2023
- 2023-12-28 JP JP2023223409A patent/JP2024019726A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017128614A5 (es) | ||
| JP2017537168A5 (es) | ||
| JP2020023518A5 (es) | ||
| JP2012153724A5 (es) | ||
| US20210220281A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| US11903908B2 (en) | Methods of administering amantadine | |
| JP2016117767A5 (es) | ||
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2011509295A5 (es) | ||
| JP2014508812A5 (es) | ||
| US20220175679A1 (en) | Compositions of midodrine and methods of using the same | |
| NZ586025A (en) | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate | |
| JP2013502446A5 (es) | ||
| JP2011510024A5 (es) | ||
| JP2013512919A5 (es) | ||
| US20110033506A1 (en) | Combination dosage form of low-dose modafinil and low-dose sildenafil | |
| HRP20211269T1 (hr) | Kompozicije prolijeka na bazi monometil fumarata | |
| WO2005055955B1 (en) | DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY | |
| JP2021001190A (ja) | トリパルス放出型賦活薬製剤 | |
| CA3021066C (en) | Oral pharmaceutical compositions of nicotinamide | |
| TWI508755B (zh) | 供三甲氧苄嗪（ｔｒｉｍｅｔａｚｉｄｉｎｅ）延長釋放之醫藥組合物 | |
| JP2015506980A5 (es) | ||
| US11033508B2 (en) | Delayed sustained release pharmaceutical compositions | |
| JP2016505628A5 (es) | ||
| JP2013536832A (ja) | ミルナシプランの制御放出医薬組成物 |